艾滋病高效抗逆转录病毒治疗所致骨质减少/骨质疏松的发病机制
Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.
作者信息
Pan George, Yang Zhen, Ballinger Scott W, McDonald Jay M
机构信息
Department of Pathology, The University of Alabama at Birmingham, 701 19 Street S., LHR 504 Birmingham, AL 35294, USA.
出版信息
Ann N Y Acad Sci. 2006 Apr;1068:297-308. doi: 10.1196/annals.1346.057.
Abstract
The advent of highly active anti-retroviral therapy (HAART) has dramatically decreased the rate of AIDS-related mortality and significantly extended the life span of patients with AIDS. A variety of metabolic side effects are associated with these therapies, one of which is metabolic bone disease. A higher prevalence of osteopenia and osteoporosis in HIV-infected patients receiving anti-retroviral therapy than in patients not on therapy has now been reported in several studies. Several factors have been demonstrated to influence HIV-associated decreases in bone mineral density (BMD), including administration of nucleoside reverse transcriptase inhibitors (NRTIs). In this article, discussion will focus on the molecular pathogenesis and treatment of HAART-associated osteopenia and osteoporosis.
摘要
高效抗逆转录病毒疗法（HAART）的出现显著降低了艾滋病相关死亡率，并显著延长了艾滋病患者的寿命。这些疗法会引发多种代谢副作用，其中之一就是代谢性骨病。多项研究现已报道，接受抗逆转录病毒治疗的HIV感染患者中，骨质减少和骨质疏松的患病率高于未接受治疗的患者。已证实有多种因素会影响与HIV相关的骨矿物质密度（BMD）降低，包括核苷类逆转录酶抑制剂（NRTIs）的使用。在本文中，讨论将聚焦于HAART相关骨质减少和骨质疏松的分子发病机制及治疗。
相似文献
1
Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.
Ann N Y Acad Sci. 2006 Apr;1068:297-308. doi: 10.1196/annals.1346.057.
2
[Influence of anitiretroviral therapy on bone tissue metabolism in patients with HIV].
Przegl Epidemiol. 2008;62(1):155-62.
3
Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4576-89.
4
[Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Zhonghua Yi Xue Za Zhi. 2012 May 8;92(17):1155-8.
5
[Multifactorial relations between HIV, HAART and bone metabolism].
Infez Med. 2006 Sep;14(3):117-24.
6
Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
Braz J Infect Dis. 2013 Nov-Dec;17(6):707-11. doi: 10.1016/j.bjid.2013.05.009. Epub 2013 Sep 25.
7
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Q J Nucl Med Mol Imaging. 2004 Mar;48(1):39-48.
8
Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
AIDS. 2001 Sep 28;15(14):1823-9. doi: 10.1097/00002030-200109280-00011.
9
Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART.
Biomed Pharmacother. 2004 Nov;58(9):505-8. doi: 10.1016/j.biopha.2004.08.019.
10
[The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Zhonghua Nei Ke Za Zhi. 2010 Aug;49(8):649-52.
引用本文的文献
1
Femoral Neck Fractures in HIV-Positive Patients: Analysis of 10 Years Short-Term Post-operative Complications.
Malays Orthop J. 2021 Nov;15(3):65-70. doi: 10.5704/MOJ.2111.010.
2
Retrospective study of the success of dental implants placed in HIV-positive patients.
Int J Implant Dent. 2019 Jun 13;5(1):30. doi: 10.1186/s40729-019-0174-6.
3
Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
J Clin Endocrinol Metab. 2017 Aug 1;102(8):2896-2904. doi: 10.1210/jc.2017-00197.
4
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.
Eur J Endocrinol. 2015 Sep;173(3):R131-51. doi: 10.1530/EJE-15-0118. Epub 2015 May 13.
5
HIV infection and osteoporosis.
Bonekey Rep. 2015 Feb 11;4:636. doi: 10.1038/bonekey.2015.3. eCollection 2015.
6
HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection.
J Osteoporos. 2013;2013:571418. doi: 10.1155/2013/571418. Epub 2013 Oct 27.
7
Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.
BMC Infect Dis. 2013 Jun 28;13:293. doi: 10.1186/1471-2334-13-293.
8
HIV and mitochondria: more than just drug toxicity.
J Infect Dis. 2012 Jun 15;205(12):1769-71. doi: 10.1093/infdis/jis105. Epub 2012 Apr 3.
9
Zidovudine and Lamivudine for HIV Infection.
Clin Med Rev Ther. 2010;2:a2004.
10
Aging, human immunodeficiency virus, and bone health.
Clin Interv Aging. 2010 Sep 23;5:285-92. doi: 10.2147/cia.s13852.
本文引用的文献
1
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.
AIDS Res Hum Retroviruses. 2006 Nov;22(11):1131-41. doi: 10.1089/aid.2006.22.1131.
2
IL-1 mediates TNF-induced osteoclastogenesis.
J Clin Invest. 2005 Feb;115(2):282-90. doi: 10.1172/JCI23394.
3
Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis.
Clin Exp Immunol. 2004 Sep;137(3):538-45. doi: 10.1111/j.1365-2249.2004.02568.x.
4
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.
J Clin Invest. 2004 Jul;114(2):206-13. doi: 10.1172/JCI15797.
5
AZT enhances osteoclastogenesis and bone loss.
AIDS Res Hum Retroviruses. 2004 Jun;20(6):608-20. doi: 10.1089/0889222041217482.
6
Antiretroviral nucleoside and nucleotide analogues and mitochondria.
AIDS. 2004 Jan 23;18(2):137-51. doi: 10.1097/00002030-200401230-00002.
7
BMD is reduced in HIV-infected men irrespective of treatment.
J Bone Miner Res. 2004 Mar;19(3):402-9. doi: 10.1359/JBMR.0301246. Epub 2003 Dec 22.
8
Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay.
J Transl Med. 2004 Mar 16;2(1):6. doi: 10.1186/1479-5876-2-6.
9
Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
J Clin Endocrinol Metab. 2004 Feb;89(2):626-31. doi: 10.1210/jc.2003-030198.
10
HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
J Biol Chem. 2003 Nov 28;278(48):48251-8. doi: 10.1074/jbc.M304676200. Epub 2003 Sep 15.
Zotero 插件